Language

Liang, Chi-Ming

LiangCM6x7Distinguished Research Fellow


Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Telephone: +886-2-2787-2099
[ CV ]

 

 

EDUCATION AND POSITIONS HELD:

  • 2009-present Distinguished Research Fellow, Genomics Research Center, Academia Sinica, Taiwan
  • 2009-2015 Chief Executive Officer, Biotechnology Incubation Center, Genomics Research Center, Academia Sinica, Taiwan
  • 2009-2013 Director, Office of Public Affairs, Academia Sinica, Taiwan
  • 2006-2009 Distinguished Investigator & Secretary General, National Health Research Institutes, Taiwan
  • 2004-Present Adjunct Research Fellow, Genomic Research Center (GRC), Academia Sinica, Taiwan (中研院基因體研究中心合聘研究員)
  • 2006-Present Adjunct Professor, National Chung Hsing University
  • 2006-Present Senior Advisor, President Office, Academia Sinica, Taiwan
  • 1997-2006 Research Fellow, Institute of Biological Chemistry, Academia Sinica, Taiwan
  • 2004-2006 Adjunct Director, GRC Incubation Center, Academia Sinica, Taiwan (中研院育成中心執行長)
  • 1997-2006 Director, Office of Public Affairs and Technology Transfer, Academia Sinica, Taiwan (中研院公共事務組主任)
  • 1994-1997 Scientific Director, Assayland, Inc., Bethesda, MD 20817
  • 1990-1994 Director of Molecular Immunology, Oncologix Inc. Gaithersburg, MD 20878
  • 1987-1990 Acting Chief, Immunology Section, Retrovirology Branch, Division of Blood & Blood Products, FDA, Bethesda, MD
  • 1986-1987 Senior Scientist, Biogen Research Corp. Cambridge, MA
  • 1982-1986 Head of Immunology, Biogen S.A., Geneva, Switzerland
  • 1980-1982 Senior Staff Fellow in the Biochemical Genetics Laboratory of Dr. Marshall Nirenberg (Nobel Laureate) at NIH
  • 1977-1980 Postdoctoral Fellow in Clinical Oncology Laboratory of Dr. Bruce Chabner (Director, Division of Cancer Treatment, NCI) at NIH
  • 1966-1970 B.S. in Pharmacy, National Taiwan University, Taiwan
  • 1971-1973 M.S. in Chemistry, National Taiwan University, Taiwan
  • 1973-1977 Ph.D. in Pharmacology, University of Arkansas for Medical Sciences
  • 1966-1970 B.S. in Pharmacy, National Taiwan University, Taiwan
  • 1971-1973 M.S. in Chemistry, National Taiwan University, Taiwan
  • 1973-1977 Ph.D. in Pharmacology, University of Arkansas for Medical Sciences

AFFILIATED PROFESSIONAL ORGANIZATIONS:

  • American Association for Cancer Research
  • The American Association of Immunologists
  • Association of Technology Managers in Taiwan 台灣技術經理人協會
  • Association of University Technology Managers
  • American Society of Biochemistry and Molecular Biology
  • International AIDS Society
  • Chinese Biochemical Society
  • Society of Chinese Bioscientists in America

AD HOC REVIEWER FOR JOURNALS AND GRANT APPLICATIONS:

  • Journal of Immunology
  • FASEB Journal
  • NIH Reproductive Biology SBIR Study Section
  • Biotech Quarterly Newsletter
  • Bio/Pharma Quarterly

RESEARCH INTERESTS:

Unlike most scientists who concentrate mainly on research, Professor Liang has utilized his multiple talents to cover 4 major areas, i.e., research, technology licensing, legal affairs, and incubation center. He is currently serving as distinguished research fellow and Chief Executive Officer at the Biotechnology Incubation Center of Genomics Research Center, Academia Sinica.

While he worked in Biogen, a leading biotechnology company during 1982-1987, he participated in many projects and helped the successful development and marketing of two multi-billion dollars drugs, i.e., alpha and beta-inteferon for Biogen.  He was also the first to produce anti-TNF monoclonal antibodies, which turned out to be a multi-billion dollars drug too. Besides research and licensing of intellectual property, He came back to Taiwan in 1997, serving as the Director of Office of Public Affairs (Technology Licensing) Academia Sinica and helped Academia Sinica to sign more than NT$2 billion of licensing contracts. He is also responsible for supervising Biotechnology Incubation Center (BIC) of Academia Sinica.  The BIC has a facility of around 90,000 square feet which is occupied by 9 portfolio companies with capital of more than NT$14 billion and 20 products in clinical trials. In addition, he has served as a scientific and technology licensing consultant for many Taiwanese government branches including National Science Council, Ministry of Economic Affairs, Department of Health, National Defense Medical College and National Taiwan University etc., to help the build-up of biotechnology and pharmaceutical industry in Taiwan through focusing on profitable projects and establishment of a stream-line cooperation system among government institutes, universities and bio-pharmaceutical industry.

SELECTED PUBLICATIONS:

  • Ho, M. Y., Liang, C. M.*, Liang, S. M. , 2015, “MIG-7 and phosphorylated prohibitin coordinately regulate lung cancer invasion/metastasis ”, Oncotarget, 6(1), 381-393. (SCI)
  • Huang CY, Liang CM, Chu CL, Peng JM, Liang SM, 2010, “A fibrillar form of fibronectin induces apoptosis by activating SHP-2 and stress fiber formation.”, APOPTOSIS, 15(8), 915-26. (SCI)
  • Y.-C. Cheng, C.-M. Liang, Y.-P. Chen, I.-H. Tsai, C.-C. Kuo & S.-M.Liang, 2009, “F-spondin plays a critical role in murine neuroblastoma survival by maintaining IL-6 expression.”, J. Neurochem., 110(3), 947-955. (SCI)
  • C.Y. Huang, C.Y.C.-M. Liang, C.L. Chu, & S.M. Liang, 2009, “Albumin fibrillization induces apoptosis via integrin/FAK/Akt pathway”, BMC Biotechnology, 9, 2. (SCI)
  • G. Nagarajan, C. C. Kuo, C. M. Liang, C. M. Chen and S. M. Liang, 2007, “Effects of CpG-B ODN on the protein expression profile of swine PBMC”, Vet Res, 38(6), 795-808. (SCI)
  • C. C. Kuo, C. M. Liang, C. Y. Lai and S. M. Liang, 2007, “Involvement of Heat Shock Protein (Hsp)90beta but Not Hsp90{alpha} in Antiapoptotic Effect of CpG-B Oligodeoxynucleotide”, J Immunol, 178(10), 6100-6108. (SCI)
  • C. C. Kuo, S. M. Liang and C. M. Liang, 2006, “CpG-B oligodeoxynucleotide promotes cell survival via up-regulation of Hsp70 to increase Bcl-xL and to decrease apoptosis-inducing factor translocation.”, J Biol Chem, 281(50), 38200-38207. (SCI)
  • S. A. Kim, C. M. Liang, I. C. Cheng, Y. C. Cheng, M. T. Chiao, C. J. Tseng, F. Lee, M. H. Jong, M. H. Tao, N. S. Yang and S. M. Liang, 2006, “DNA vaccination against foot-and-mouth disease via electroporation: study of molecular approaches for enhancing VP1 antigenicity”, J Gene Med, 8(9), 1182-1191. (SCI)
  • Kim, S.-A., Liang, C.-M., Chiao, M.-T., Cheng, I.-C., Lee, F., Jong, M.-H., Tao, M.-H., Tseng, C.J., Yang, N.-S., and Liang, S.-M., 2006, “DNA vaccination against foot-and-mouth disease via electroporation: Study of molecular approaches for enhancing VP1 antigenicity.”, J. Gene Med., 8(9), 1182-1191. (SCI)
  • C. C. Kuo, W. T. Lin, C. M. Liang and S. M. Liang, 2006, “Class I and III Phosphatidylinositol 3'-Kinase Play Distinct Roles in TLR Signaling Pathway”, J Immunol, 176(10), 5943-5949. (SCI)
  • Cheng-Chin Kuo, Chu-Wei Kuo , Chi-Ming Liang, Shu-Mei Liang, 2005, “A transcriptomic and proteomic analysis of the effect of CpG-ODN on human THP-1 monocytic leukemia cells”, Proteomics, 5(4), 894-906. (SCI)
  • J. M. Peng, S. M. Liang and C. M. Liang, 2004, “VP1 of foot-and-mouth disease virus induces apoptosis via Akt signaling pathway”, J Biol Chem, 279(50), 52168-52174. (SCI)
  • J. H. Wang, C. M. Liang, J. M. Peng, J. J. Shieh, M. H. Jong, Y. L. Lin, M. Sieber and S. M. Liang, 2003, “Induction of immunity in swine by purified recombinant VP1 of foot-and-mouth disease virus”, Vaccine, 21, 3721-3729. (SCI)
  • C. M. Liang, 1999, “Academic point of view on Taiwan's implementation of Health Food Control Act”, 87-92.
  • J. Pugin, M. C. Widmer, S. Kossodo, C. M. Liang, H. L. n. Preas and A. F. Suffredini, 1999, “Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators”, American Journal of Respiratory Cell and Molecular Biology, 20(3), 458-464. (SCI)
  • C. M. Liang, 1999, “Treatment of vascular leakage and related syndrome such as septic shock by administration of metalloproteinase inhibitors”, US patent, #5,866,570.
  • P. G. Johnston, 1996, “Monoclonal antibodies specific for human thymidylate synthase”, US patent, 6,221,620.
  • D. W. Visscher, M. Hoyhtya, S. K. Ottosen, C. M. Liang, F. H. Sarkar, J. D. Crissman and R. Fridman, 1994, “Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence”, Int J Cancer, 59(3), 339-344. (SCI)
  • M. Hoyhtya, R. Fridman, D. Komarek, K. Porter Jordan, W. G. Stetler Stevenson, L. A. Liotta and C. M. Liang, 1994, “Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies”, Int J Cancer, 56(4), 500-505. (SCI)
  • M. K. Bhat, C. Parkison, P. McPhie, C. M. Liang and S. Y. Cheng, 1993, “Conformational changes of human beta 1 thyroid hormone receptor induced by binding of 3,3',5-triiodo-L-thyronine”, Biochemical and Biophysical Research Communications, 195(1), 385-392. (SCI)
  • S. P. Jiang, 1993, “Development of novel immunoassays to distinguish between the free and complexed forms of matrix metalloproteinase-2 (MMP-2)”, FASEB J, 7, 1211. (SCI)
  • R. Fridman, R. E. Bird, M. Hoyhtya, M. Oelkuct, D. Komarek, C. M. Liang, M. L. Berman, L. A. Liotta, W. G. Stetler Stevenson and T. R. Fuerst, 1993, “Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme”, Biochem J, 289, 411-416. (SCI)

PATENTS:

  • Johnston, P.G., Allegra, C.J., Chabner, B.A., and Liang, C.-M., (1992) Monoclonal antibodies specific for human thymidylate synthase. CA 2109086.
  • Liang, C.-M., Turner, N.A., and Witiak, D.T. (1993) Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors. AU 4373993 9.
  • Liang, C.-M., Turner, N.A., and Witiak, D.T. (1999) Treatment of vascular leakage and related syndrome such as septic shock by administration of matrix metalloproteinase inhibitors. US 5866570.
  • Johnston, P.G., Allegra, C.J., Chabner, B.A., and Liang, C.-M., (2001) Monoclonal antibodies specific for human thymidylate synthase. US 6221620.
  • Liang, S.-M., Peng, J.-M., and Liang, C.-M., (2008) Apoptosis-inducing polypeptides. US 7323546
  • Liang, S.-M., Peng, J.-M., and Liang, C.-M., (2009) “Apoptosis-inducing polypeptides” US 7488800
  • Liang, S.-M., Peng, J.-M., and Liang, C.-M., (2010) “Apoptosis-inducing polypeptides” US 7700730
  • Liang, S. M., Huang, C. Y., Liang, C. M. (2010) Method of producing fibrillar proteins. GB 2460283
  • Huang, C. Y., Liang, S. M., Liang, C. M. (2010) Fibrillar fibronectin and uses thereof. GB 2460966
  • Liang, S. M., Huang, C. Y., Liang, C. M. (2011) An isolated fibrillar structure protein of the foot-and-mouth disease virus and uses thereof. GB 2464028
  • Liang, S. M., Huang, C.Y., Chen, Y.P., Liang, C.M.(2012) Process to produce fibrillar proteins US 8268974.
  • Liang, S. M., Liang, C. M. (2013) Anti-tumor fibrillar human serum albumin methods and composition US 8357652
  • Liang SM, Liang CM, Huang CY, Chen YP. Process to produce fibrillar proteins and method of treatment using fibrillar proteins. Taiwan Patent No. TWI392739 (2013)
  • Liang SM, Peng JM, Liang CM. Apoptosis-inducing polypeptides. EP Patent No. 2,465,531B1(2013)